This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Khoschsorur, G. Articles by Tscheliessnigg, K.H. Search for Related Content PubMed PubMed Citation Articles by Khoschsorur, G. Articles by Tscheliessnigg, K.H. Social Bookmarking                         What's this?

The Determination of Metabolite M 17 and Its Meaning for Immunosuppressive Cyclosporin Therapy

Departments of Surgery and Clinical Laboratory, University of Graz, Graz, Austria.

T. Auer, MD

Departments of Transplantation, University of Graz, Graz, Austria.

G. Lanzer, MD

Departments of Surgery and Clinical Laboratory, University of Graz, Graz, Austria.

P. Petritsch, MD

Departments of Urology, University of Graz, Graz, Austria.

H. Holzer, MD

Departments of Internal Medicine, University of Graz, Graz, Austria.

K.H. Tscheliessnigg, MD

Departments of Transplantation, University of Graz, Graz, Austria.

Cyclosporin A (CyA) is intensively metabolized by the hepatic cytochrome p450 III monooxygenase A system in the human liver, the most important metabolites being M1, M17, and M21. Because CyA and its metabolites have nephrotoxic, hepatotoxic, and neurotoxic side effects, CyA dosage must be calculated to avoid the risk of organ rejection through underdosage and toxic organ damage through overdosage or accumulation of metabolites.

In this study, we determined the whole-blood concentrations of cyclosporin and metabolite M17 by high-pressure liquid chromatography (HPLC) and by monoclonal specific and polyclonal nonspecific fluorescence polarization immunoassay (Abbott) in patients after immunosuppressive treatment.

Patients with different resorption and metabolization rates showed high individual variations. CyA concentrations in patients with good liver function and low concentra tions of CyA metabolites showed a good correlation between the HPLC and the FPIA (TDx-monoclonal assay) methods in ranges between 25 and 180 ng/mL. TDx-mono clonal was not always as precise as HPLC. In cases of metabolic disorders, we found false high CyA concentrations assayed with the immunologic method, caused by a cross- reaction of the elevated metabolite concentration. We found that HPLC rendered more information about the extent of immunosuppressive activity and the metabolization rate and showed a good correlation with the concentration of metabolite M17 and total metabolites measured with the Abbott CyA polyclonal kit.

Angiology, Vol. 49, No. 4, 307-314 (1998)
DOI: 10.1177/000331979804900409


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?